1-1 of 1
Ayako Arai
Close
Save search
Sort by
Journal Articles

JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study

Open Access
Clinical Trials & Observations
Yu Uemura, Masahide Yamamoto, Masataka Ishimura, Hirokazu Kanegane, Akihisa Sawada, Akihiro Hirakawa, Ken-Ichi Imadome, Mayumi Yoshimori, Masashi Nagata, Kouhei Yamamoto, Norio Shimizu, Ryuji Koike, Ayako Arai
Journal: Blood Neoplasia
Blood Neoplasia (2024) 2 (1): 100053.
https://doi.org/10.1016/j.bneo.2024.100053
Published: 2024
Includes: Supplemental data